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AbstrAct
Lung cancer is the leading cause of cancer-related 
deaths in the world. Immune checkpoint inhibitors (ICI) 
stimulate cytotoxic lymphocyte activity against tumour 
cells. These agents are available for the treatment of non-
small cell lung cancer (NSCLC) after failure of platinum-
based therapy. One recent study has demonstrated 
that ICI monotherapy was superior to platinum-based 
chemotherapy for first-line treatment. Nevertheless, this 
benefit was only for a minority of the population (30%) 
whose tumour programmed death receptor ligand-1 
(PD-L1) expression was above 50%. Therefore, several 
strategies are under investigation. One option for patients 
with PD-L1 expression lower than 50% may be the 
combination of ICI with platinum-based chemotherapy or 
with ICIs against different targets. However, all of these 
combinations are at an early stage of investigation and 
may be very expensive or toxic, producing several harmful 
adverse events.
Lung cAncer epidemioLogy
Lung cancer is the most common malig-
nancy worldwide with more than 1.8 million 
new cases diagnosed in 2012.1 Lung cancer 
mortality is also high; North-American epide-
miological data showed that the incidence 
and mortality rates of lung cancer in the USA 
was 57.3 and 46.0 per 100 000, respectively, 
with 224 390 new cases and 158 050 deaths 
estimated in 2016.2 3 As a result, lung cancer 
is the most common cause of cancer-related 
deaths in the world with more than 1.5 million 
deaths worldwide in 2012.1 3 Recent trends 
suggest that in the USA overall lung cancer 
mortality rates are decreasing, but for women 
reduction in mortality is occurring at a dispa-
rately lower rate than men, probably because 
of smoking habits.4
Non-small cell lung cancer (NSCLC) is a 
histological class comprising approximately 
85% of all lung cancers and at diagnosis a 
majority of patients with NSCLC have meta-
static disease.3 5
treAtment of metAstAtic nscLc
In the past, the outcome of treatment for 
patients with advanced NSCLC was poor, 
with a median survival of 4–5 months and a 
1-year survival rate of 10%.6 Platinum-based 
therapies as well as non-platinum based 
single agents like paclitaxel, docetaxel, 
gemcitabine, vinorelbine and irinotecan have 
improved the median survival to 7–9 months 
and 1-year survival rate to over 35%.7 There-
after, trials comparing single-agent cisplatin 
with cisplatin in combination with newer 
agents have showed significant improvement 
in overall survival (OS) with combination 
therapy.8 9 Among combinations under inves-
tigation, none proved superior to the others.10
More recently, agents like pemetrexed and 
bevacizumab combined with platinum-based 
therapies for four to six cycles and single-
agent or combination maintenance until 
disease progression have further improved 
survival.11–14 However, both drugs are 
approved only for patients with non-squamous 
histology (non-squamous cell carcinoma). 
Pemetrexed has been shown to decrease 
the survival rate among squamous histology 
(squamous cell carcinoma (SCC)),11 and 
bevacizumab had a higher risk of haemop-
tysis for SCC as previously observed in phase 
II studies.12
Despite all these improvements, the median 
progression-free survival (PFS) observed with 
chemotherapy is around 6 months and the 
median OS do not surpass 15 months in most 
trials of non-targeted agents.13 14
In the last decade, better understanding of 
molecular pathways led to the development 
of targeted therapies and personalised medi-
cine in lung cancer. The human epidermal 
growth factor receptor (EGFR) is the most 
studied target in lung cancer. This is a trans-
membrane receptor with an extracellular 
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portion containing a binding domain for growth factors 
and an intracellular domain including tyrosine kinase 
that through the RAS/RAF/MEK/ERK pathway leads 
cell proliferation, angiogenesis and cellular immor-
tality.15 Mutations of the gene encoding EGFR are present 
in 15% to 60% of adenocarcinomas, and are related to 
Asian ethnicity, female gender and absence of smoking.16
When mutated, the receptor remains active and 
cellular proliferation signals become continuous and 
disinhibited. Treatment with tyrosine kinases inhibi-
tors (TKIs) lead to tumour responses in over 50% of 
patients and nearly doubles median PFS.16–18 Another 
key oncogenic mutation has been discovered and 
studied: the anaplastic lymphoma kinase (ALK) gene. 
ALK is rearranged in up to 6% of patients with NSCLC.15 
ALK-targeted TKIs have been developed and show similar 
efficacy as EGFR TKIs.19
After progression on first-line platinum-based combi-
nation therapy or targeted agents, there are only a few 
treatment options available. Docetaxel, pemetrexed and 
erlotinib20 achieve a median PFS between 2 and 3 months 
and median OS of around 8 months, underscoring the 
need for more treatment options.20
nscLc And the immune system
Tumour cells (TCs) acquire several mutations during 
their development. These mutations may lead to TC 
immortality and aberrant proliferation. However, some 
of these mutations can produce aberrant proteins that 
can serve as neoepitopes, which are recognised by the 
immune system.21 Not all tumours have the same burden 
of mutations, and it is believed that a higher tumour 
burden leads to higher immunogenicity.21 Squamous and 
non-squamous NSCLCs, as well as melanoma, have the 
highest burden of mutations, and they were among the 
first studied in the development of immunotherapy.22
The immune system is able to recognise and destroy 
TCs as well as pathogenic agents. Nevertheless, one of 
the hallmarks of cancer is its ability to evade the immune 
system.23 There are many complex interactions between 
antigen presenting cells, lymphocytes and TCs. The most 
studied is the link between the lymphocytic membrane 
receptor, programmed cell death 1 (PD-1) and its ligands 
1 or 2 (PD-L1 or PD-L2), which are often expressed by 
TCs. The interaction between PD-1 and PD-L1/PD-L2 
inhibits lymphocytes and stimulates their apoptosis.21
Immune checkpoint inhibitors (ICIs) are an emerging 
class of immunotherapy which stimulate lymphocytes 
against TCs and might be better tolerated than cytotoxic 
chemotherapy. The most studied class in the treatment of 
NSCLC is anti-PD1/anti-PD-L1 drugs.21
immune checkpoint inhibitors for second-Line 
treAtment of nscLc: phAse i/ii triAL dAtA
Nivolumab is a fully human monoclonal antibody 
against PD-1. It was the first immune checkpoint inhib-
itor approved for second-line treatment of NSCLC. 
CheckMate-003 was a phase Ib clinical trial that assessed 
nivolumab at 1, 3 or 10 mg/kg every 2 weeks in 129 heavily 
pretreated patients with advanced NSCLC regardless of 
tumour histology.24 The median OS was 9.9 months, and 
the 1-year survival rate was 42%.24 The objective response 
rate (ORR) was 17%.24 Nivolumab was well tolerated 
(14% of patients had grade 3 or 4 adverse events);how-
ever there were three fatal cases of pneumonitis.24 These 
results generated significant enthusiasm for further devel-
opment of lung cancer immunotherapy.
CheckMate-063, a phase II clinical trial, evaluated the 
efficacy and safety of nivolumab at 3 mg/kg every 2 weeks 
for 117 patients previously treated for squamous NSCLC.25 
The 1-year survival rate was 40.8%, and the median OS was 
8.2 months; 14.5% of patients had a partial response.25 
There were four non-fatal cases of grade 3 pneumonitis 
and little severe toxicity (17% of patients had grade 3 or 
4 adverse events).25 Three-quarters of patients had their 
tumour sample assessed for PD-L1 expression and the 
cut-off value for positivity was considered to be 5%. The 
ORR was higher for patients with PD-L1 above the cut-off 
than those below (24% and 14%, respectively).24
Pembrolizumab is a humanised monoclonal antibody 
that targets the PD-1 receptor. KeyNote-001 was a large 
phase Ib trial that included 495 patients with advanced 
NSCLC (80% of whom were previously treated) who 
received pembrolizumab at 2 or 10 mg/kg every 3 weeks 
or 10 mg/kg every 2 weeks.26 The median OS was 12 
months for all patients (9.3 months for previously treated 
patients and 16.2 months for previously untreated 
patients); 19.4% of all patients had partial responses.26 
All patients had their tumour samples assessed for PD-L1 
expression and the ORR was directly proportional to 
PD-L1 expression (8.1% for PD-L1<1%, 12.9% for PD-L1 
1%–24%, 19.4% for PD-L1 25%–49%, 29.6% for PD-L1 
50%–74% and 45.4% for PD-L1≥75%).26 This study also 
reported that patients who expressed PD-L1 had higher 
survival rates than those who did not: the median OS was 
around 9 months for patients with PD-L1<1% or PD-11%–
49% and the median OS was not reached for patients with 
PD-L1≥50%.26
Atezolizumab is a humanised monoclonal anti-
body that acts in the same pathway as nivolumab and 
pembrolizumab, but its target is PD-L1. This monoclonal 
antibody was studied in a dose escalation phase Ia trial 
that included 88 patients with advanced NSCLC (11% of 
them previously untreated).27 The ORR and median OS 
for all patients were 23% and 16 months, respectively.27 In 
this study, PD-L1 expression ≥50% in TCs or tumour-in-
filtrating cells resulted in higher ORR (48% vs 16%) 
and a longer median OS (18 months vs 16 months).27 
Atezolizumab was well tolerated with 11% of patients 
experiencing at least one grade 3 to 4 adverse event; there 
were four cases of pneumonitis, but none was severe.27
Avelumab is a fully human monoclonal antibody against 
PD-L1. It was studied at a dose of 10 mg/kg every 2 weeks 
in a large phase Ib trial that included 184 patients with 
previously treated NSCLC.28 The ORR with avelumab was 
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13.6%, the median OS 8.4 months and the 1-year survival 
rate was 37%.28 A majority of patients had their tumour 
samples assessed for PD-L1 expression (142) based 
on a cut-off of ≥1% TCs with staining of any intensity.28 
Although differences were not statistically significant, 
PD-L1 positive patients had higher ORR (15.6% vs 10%) 
and longer median OS (8.9 months vs 4.6 months).28 The 
safety profile was compatible with previously described 
results with 12.5% of patients experiencing adverse events 
of grade 3 to 4, including two cases (1.1%) of pneumo-
nitis, one of which was fatal.28
Durvalumab is a fully human IgG1 antibody against 
PD-L1. The drug was studied in a dose escalation trial 
that included 228 patients with advanced NSCLC (12% 
of them previously untreated).29 The ORR for all patients 
was 16% (15% for patients previously treated) and the 
median OS was 8.9 months for PD-L1-negative patients 
and the median OS was not reached for PD-L1-posi-
tive patients.29 The ORR was also associated with PD-L1 
expression (27% for PD-L1-positive patients and 5% for 
PD-L1-negative patients).29 Durvalumab was well toler-
ated; there were only three non-fatal cases of pneumonitis 
and only 8% of the patients had adverse event of grade 3 
to 4—table 1).
immune checkpoint inhibitors for the second-Line 
treAtment of nscLc: rAndomised cLinicAL triALs
CheckMate-017 evaluated nivolumab 3 mg/kg every 2 
weeks versus docetaxel 75 mg/m² every 3 weeks for the 
second-line treatment of patients with squamous NSCLC.30 
The study randomised 272 patients (135 for nivolumab 
and 137 for docetaxel).30 Nivolumab showed a statistically 
significant benefit in ORR (20% vs 9%; p=0.008), PFS(me-
dian 3.5 months vs 2.8 months; HR 0.62, 95% CI 0.47 to 
0.81; p<0.001), and OS (median 9.2 months vs 6 months; 
HR 0.59, 95% CI 0.44 to 0.79; p<0.001).30 Nivolumab was 
better tolerated than docetaxel; treatment-related adverse 
events leading to discontinuation were less frequent in 
the nivolumab group (3% vs 10% of patients).30 Myelo-
toxicity occurred in up to 30% of patients treated with 
docetaxel and was a rare event (1% to 2% of patients) 
with nivolumab.30 Pneumonitis occurred in six cases 
with nivolumab, but none was severe.30 Furthermore, 
there were no deaths related to the treatment in the 
nivolumab group, and three deaths related to therapy in 
the docetaxel arm.30
CheckMate-057 compared nivolumab 3 mg/kg every 2 
weeks with docetaxel 75 mg/m² every 3 weeks in patients 
with advanced non-squamous NSCLC.31 Five hundred and 
eighty-two patients were randomly assigned to nivolumab 
(292 patients) or docetaxel (290 patients).31 As in Check-
Mate-017, nivolumab was better tolerated (5% of patients 
discontinued nivolumab due to adverse events versus 
15% of those treated with docetaxel) and was associated 
with increased ORR compared with docetaxel (19% vs 
12%; p=0.02).31 There was no reported benefit in PFS 
and this may be due to the atypical pattern of response 
observed with immunotherapy (such as pseudoprogres-
sion).32 Nivolumab was associated with increased median 
OS (12.2 months vs 9.4 months; HR 0.72, 95% CI 0.60 to 
0.88; p<0.001) when compared with docetaxel.31
Both studies retrospectively evaluated PD-L1 expres-
sion as a predictive biomarker. PD-L1-positive patients 
had better ORR and OS compared with PD-L1-nega-
tive patients.30 31 Interestingly, the correlation between 
PD-L1 expression and clinical benefits, such as ORR, PFS 
and OS, were more significant for patients with non-squa-
mous tumours.30 31
KeyNote-010 was a phase IIb/III trial evaluating the 
efficacy of pembrolizumab versus docetaxel in patients 
with previously treated advanced NSCLC with PD-L1 
expression of at least 1%.33 The authors screened 2222 
patients’ tumour samples for PD-L1 expression and 
found 1475 (66%) with at least 1% expression.33 Inves-
tigators randomised 1034 patients in a 1:1:1 ratio to 
receive pembrolizumab 2 mg/kg every 3 weeks, pembroli-
zumab 10 mg/kg every 3 weeks or docetaxel 75 mg/m² 
every 3 weeks.33 Pembrolizumab improved the median 
OS compared with docetaxel (pembrolizumab 2 mg/kg 
vs docetaxel: 10.4 months vs 8 months; HR 0.71, 95% CI 
0.58 to 0.88; p=0.0008; pembrolizumab 10 mg/kg vs 
docetaxel: 12.7 months vs 8 months; HR 0.61, 95% CI 0.49 
to 0.75; p<0.0001).33 The ORR was also improved (18% 
for patients treated with pembrolizumab 2 or 10 mg/
Table 1 Summary of results from non-randomised clinical trials
Study Drug Population n ORR OS
CheckMate-00324 Nivolumab NSCLC previously treated 129 17% 9.9 months
CheckMate-06325 Nivolumab SCC previously Treated 117 14.5% 8.2 months
KeyNote-00126 Pembrolizumab NSCLC 80% previously treated 495 19.4% 12 months
PCD4989 g27 Atezolizumab NSCLC 89% previously treated 88 23% 16 months
Javelin28 Avelumab NSCLC 99% previously treated 184 13.6% 8.4 months
Rizvi29 Durvalumab NSCLC 88% previously treated 228 16% 8.9 months
(PD-L1 −)
NR
(PD-L1 +)
NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1, programmed death receptor ligand-1.
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kg and 9% for patients treated with docetaxel).33 The 
benefits with pembrolizumab were more pronounced 
among patients with PD-L1 expression ≥50% (HR for 
OS was 0.50, 95% CI 0.36 to 0.70; p<0.0001).33 Severe 
adverse events were less common for patients treated with 
pembrolizumab (13% for pembrolizumab 2 mg/kg, 16% 
for pembrolizumab 10 mg/kg, and 35% for docetaxel).33 
The most common side effects in patients treated with 
pembrolizumab were decreased appetite, fatigue, rash 
and nausea.33
POPLAR was a multicentre, randomised, phase II trial 
comparing atezolizumab 1200 mg every 3 weeks versus 
docetaxel 75 mg/m² every 3 weeks for patients with 
NSCLC who progressed on platinum-doublet chemo-
therapy.34 Two hundred and eighty-seven patients were 
included in this study: 144 were randomly allocated to 
receive atezolizumab and 143 to the docetaxel group.34 
Atezolizumab improved median OS (12.6 months for 
atezolizumab vs 9.7 months for docetaxel), although the 
ORR was not improved in the overall population (15% 
for both groups).34 All patients had their tumour samples 
assessed for PD-L1 expression and the researchers evalu-
ated TCs as well as tumour-infiltrating cells.34 The ORR 
with atezolizumab was directly proportional to the PD-L1 
expression (8% for patients with PD-L1 negative and 38% 
for patients with PD-L1≥50%).34 In the atezolizumab arm, 
not only was OS higher among PD-L1-positive patients 
but this subgroup were the only group with a statistically 
significant improvement compared with docetaxel.34 OS 
HR for all patients was 0.77 (95% CI 0.55 to 1.06); HR for 
PD-L1≥50% was 0.46 (95% CI 0.19 to 1.09)—median OS 
not reached with atezolizumab; HR for PD-L1-negative 
patients was 1.12 (95% CI 0.64 to 1.93)—median OS 9.7 
months with atezolizumab.34
The OAK tial evaluated atezolizumab for the second-
line treatment of NSCLC regardless of tumour histology 
or PD-L1 expression; however, there was a stratification 
according to PD-L1 expression.35 Investigators enrolled 
1225 patients and randomised them to atezolizumab 
(1200 mg every 3 weeks) or docetaxel (75 mg/m² every 
3 weeks).35
In the preliminary analysis of data from 850 patients 
(425 included in each treatment arm), the OS improved 
by 27% in the patients receiving atezolizumab compared 
with those treated with docetaxel (median OS was 13.8 
months vs 9.6 months; HR 0.73; 95% CI 0.62 to 0.87).35 
There was no improvement in ORR (14% for atezoli-
zumab vs 13% for docetaxel).35
When patients were stratified according to their level 
of PD-L1 expression, the OS was 59% greater among 
patients with PD-L1 expression ≥50% or≥10% in the 
infiltrating cells who were treated with atezolizumab, 
compared with the same group treated with docetaxel.35 
The median OS was 20.5 months for atezolizumab 
and 8.9 months for docetaxel (HR 0.41; 95% CI 0.27 
to 0.64).35 However, even inpatients without PD-L1 
expression, there was a significant improvement in OS 
with atezolizumab compared with docetaxel.35 Among 
PD-L1-negative patients, the median OS was 12.6 months 
for atezolizumab versus 8.9 months for docetaxel (HR 
0.75; 95% CI 0.59 to 0.96).35
PD-1 blockade can enhance lymphocyte function in a 
diversity of organs and systems while PD-L1 blockade may 
stimulate lymphocytes only in the tumour microenviron-
ment because PD-L1 is much more common in TCs than 
normal cells.21 Although many scientists expected a more 
favourable toxicity profile because of high specificity of 
PD-L1 blockade, atezolizumab showed a similar adverse 
events profile to those previously reported for anti-PD-1 
drugs.35
Curiously, an anti-PD-L1 treatment was the first immune 
checkpoint inhibitor that showed statistically significant 
OS improvement among PD-L1-negative patients. In 
the literature, this phenomenon remains unexplained. 
An often quoted hypothesis is that differences in PD-L1 
testing assay used in each study might explain these 
different results.36 The specific SP142 monoclonal anti-
body used in the trials with atezolizumab seems to be less 
sensitive than other monoclonal antibodies such as 22C3.
All randomised clinical trial that included patients 
with both squamous and non-squamous histology 
found improvements in OS similar in both histology 
subtypes.33–35 Furthermore, all randomised clinical trial 
showed that patients with EGFR mutations had lower 
benefits with immunotherapy compared with patients 
who were EGFR wild type (table 2).31 33–35
Table 2 Randomised clinical trial data
Immunotherapy versus 
docetaxel
ORR versus 
docetaxel
Median PFS 
versus 
Median OS versus 
docetaxel HR for OS (95% CI)
CheckMate-01730 Nivolumab 20% vs 9% 3.5 m vs 2.8 m 9.2 m vs 6.0 m 0.59 (0.44 to 0.79)
CheckMate-05731 Nivolumab 19% vs 12% 2.3 m vs 4.2 m 12.2 m vs 9.4 m 0.73 (0.59 to 0.89)
KeyNote-01033 Pembrolizumab 2 mg/kg 18% vs 9% 3.9 m vs 4.0 m 10.4 m vs 8.5 m 0.71 (0.58 to 0.88)
Pembrolizumab 10 mg/
kg
18% vs 9% 4.0 m vs 4.0 m 12.7 m vs 8.5 m 0.61 (0.49 to 0.75)
POPLAR34 Atezolizumab 15% vs 15% 2.7 m vs 3.0 m 12.6 m vs 9.7 m 0.73 (0.53 to 0.99)
OAK35 Atezolizumab 14% vs 13% 2.8 m vs 4.0 m 13.8 m vs 9.6 m 0.73 (0.62 to 0.87)
ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
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the tALe of the tAiL
The main issue to support immunotherapy is the exis-
tence of a proportion of patients who will reach a life-time 
long benefit with the treatment. This is ‘The Tale of the 
Tail’ that had been observed previously in the treatment 
of melanoma.37 However, new data indicate that the same 
phenomenon can also occur in the second-line treatment 
of NSCLC.
The first evidence of this derives from the data of 
2-year follow-up of previously published randomised 
clinical trials. Data presented at the 2016 ASCO Annual 
Meeting after a 2-years follow-up of the CheckMate-017 
and CheckkMate-057 studies show that the 2-year survival 
rate is higher with nivolumab compared with docetaxel.38 
Among patients with squamous histology tumours, the 
2-year survival rate is 23% with nivolumab versus 8% with 
docetaxel.38 Among patients with non-squamous histology 
tumours, these values  are 29% and 16%, respectively.38
A similar effect occurred with pembrolizumab versus 
docetaxel. After a minimum follow-up of 2 years, the 
survival rate was 30.1% with pembrolizumab 2 mg/kg, 
37.5% with pembrolizumab 10 mg/kg versus 14.5% with 
docetaxel.39
Recently, at the 2017 AACR Annual Meeting, a 5-year 
follow-up data from the phase I study of nivolumab was 
released.40 According to the authors, the 5-year survival 
rate was 16%, which is an expressive value compared 
with the 4% reached with chemotherapy.40 The authors 
assessed the PD-L1 expression of 10 out 16 patients alive 
after 5 years. 70% of these patients had a PD-L1 expres-
sion ≥1%.40
In addition, a model of life-time long survival was devel-
oped for pembrolizumab versus docetaxel.41 The model 
was based on the risk of disease progression not being 
constant (the risk of disease progression is higher at the 
beginning of treatment and decreases progressively).41 
According to the model, the risk of disease progression 
is zero after some time (when the tail of the curve is 
reached).41
The initial model based on KeyNote-010 published data 
found a 5-year survival rate of 25.3%.41 Subsequently, the 
model was repeated based on the prolonged follow-up 
data previously described and the rate found was 21.5%.41 
For control purposes, the group of patients treated with 
docetaxel had a 5-year survival rate estimated at 4.3%, 
being fully compatible with the expected values  classi-
cally.41
The main criticisms of this model is that it does not 
represent real follow-up data. In addition, the model used 
data derived from randomised clinical trial that may not 
represent the real-life population.
immune checkpoint inhibitors in the first-Line 
treAtment of nscLc
The next step was the assessment of immunotherapy in 
the first-line treatment of NSCLC (table 3). Many of the 
phase I/II studies cited above included a few patients who 
were previously untreated, showing promising results, 
especially for those whose TCs expressed PD-L1.26–29 For 
this reason, all phase III trials enrolled only PD-L1-posi-
tive patients to compare immunotherapy as a single agent 
with a platinum-based regimen for the first-line treatment 
of NSCLC.42 43 The studies showed discrepant results and 
the PD-L1 positivity threshold used for patient selection 
was the main difference between CheckMate-026 and 
KeyNote-024.42 43 All patients in both studies were EGFR 
and ALK wild type.42 43
CheckMate-02642 enrolled 541 patients who received 
nivolumab 3 mg/kg every 2 weeks until disease progres-
sion or investigator’s choice of platinum-based doublet 
(ICPD) chemotherapy every 3 weeks for up to six 
cycles.42 Patients in the ICPD arm who achieved partial 
response or stable disease after six cycles could be main-
tained on chemotherapy until disease progression or 
unacceptable toxicity.42
There were more women in the ICPD than in the 
nivolumab arm (45% vs 32%).42 There were no other 
significant differences in key baseline characteristics 
between the two groups.42 The two most commonly used 
chemotherapy doublets were pemetrexed/carboplatin 
(43.7%) and pemetrexed/cisplatin (32.7%) and about 
40% of patients received maintenance pemetrexed.42 
Although the threshold of PD-L1 positivity in Check-
Mate-026 was ≥1%, the primary end point of the study 
was the PFS inpatients with PD-L1≥5% (423 patients).42
Nivolumab had a worse PFS compared with ICPD 
(median PFS of 4.2 months vs 5.9 months; (HR 1.15; 
Table 3 Data on immunotherapy as single agent for the first-line treatment of NSCLC
CheckMate-02642 KeyNote-02443
Immunotherapy vs ICPD Nivolumab Pembrolizumab
ORR vs ICPD 26% vs 34% 45% vs 28%
Median PFS vs ICPD 4.2 m vs 5.9 m 10.3 m vs 6.0 m
Median OS vs ICPD 14.4 m vs 13.2 m NR both arms
HR for OS (95% CI) PD-L1≥5% 1.02 (0.80 to 1.30) NA
HR for OS (95% CI) PD-L1≥50% 0.90 (0.67 to 1.32) 0.60 (0.41 to 0.89)
ICPD, immune-check points drug; NA, not applicable; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; 
PFS, progression-free survival.
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95% CI 0.91 to 1.45).42 Median OS inpatients with PD-L1 
expression ≥5% was 14.4 months with nivolumab and 
13.2 months with chemotherapy (HR 1.02; 95% CI 0.80 
to 1.30).42 The ORR was 26.1% with nivolumab and 
33.5% with chemotherapy.42 Even among patients with 
PD-L1 expression ≥50%, a benefit was not observed for 
nivolumab versus chemotherapy, with a HR for PFS of 
1.07 and a HR of 0.90 for OS.42
Toxicities in both treatment groups were consistent 
with previous reports. The most common adverse events 
with nivolumab were fatigue (21% vs 35.4% with chemo-
therapy), diarrhoea (13.9% vs 12.9%), decreased appetite 
(12% vs 27.8%) and nausea (11.6% vs 48.3%).42 Grade 
3/4 adverse events were uncommon with nivolumab.42
In contrast with these findings, KeyNote-024 showed 
significantly better clinical outcomes for pembrolizumab 
than chemotherapy inpatients who expressed PD-L1 at a 
higher threshold of 50% or greater.43
Overall, 30.2% of 1653 samples expressed PD-L1 
on ≥50% of cells by immunohistochemistry.43 Of those 
who met the PD-L1 expression requirements, 305 were 
randomised to receive pembrolizumab (154) or ICPD 
(151), which most commonly included pemetrexed/
carboplatin (44%).43
The trial achieved its primary end point showing that 
patients treated with pembrolizumab had a longer PFS 
than those who received chemotherapy.43 The median 
PFS was 10.3 months with pembrolizumab versus 6 
months with chemotherapy (HR 0.50; 95% CI 0.37 to 
0.68).43 Although the follow-up period was relatively 
short, 6 month OS rate was 80.2% with pembrolizumab 
versus 72.4% with chemotherapy (HR 0.60; 95% CI 0.41 
to 0.89).43 The ORR was also higher with pembrolizumab 
(45% vs 28%; p=0.0011).43
Fewer treatment-related adverse events were seen with 
pembrolizumab versus chemotherapy (all grades: 73.4% 
vs 90%; grade 3% to 5 26.6% vs 53.3%).43 The most 
common toxicity with pembrolizumab were diarrhoea 
(14.3%), fatigue (10.4%) and fever (10.4%).43
These results have since changed the management 
of advanced NSCLC. Patient whose tumours have 50% 
or greater expression of PD-L1 should now be offered 
treatment with pembrolizumab and the agent has been 
approved in a number of jurisdictions.
Figure 1 summarises the guideline for the treatment of 
NSCLC after the development of immunotherapy.
the roLe of pd-L1 expression As A biomArker
PD-L1 expression is a logical predictor of responsiveness 
to PD-1/PD-L1 inhibitors as it is mechanically essential in 
the immune checkpoint pathway.21 Two recent meta-anal-
yses have shown the response to immunotherapy 
increases proportionally with the extent of PD-L1 expres-
sion in TCs.44–46 As a general model, the ORR is 2 to 3 
times higher for PD-L1-positive patients.45 46 Moreover, 
patients with PD-L1-positive tumours have higher survival 
rates when treated with ICIs.45 46
The indication of immunotherapy as a single agent 
for the first-line treatment of NSCLC is well established. 
As cited above, patients must have at least 50% of PD-L1 
expression and a wild type EGFR and ALK to be eligible 
for pembrolizumab. New combinations are under inves-
tigation to improve immunogenicity of tumours with 
PD-L1 <50% and improve the outcomes with immuno-
therapy. These combinations will be discussed in the next 
session.
For second-line therapy, ICIs are indicated as 
single agents regardless of PD-L1 expression (except 
pembrolizumab that is indicated only for patients with 
at least 1% of TCs expression). This indication has 
produced significant discussion regarding the high 
cost of treatment in this clinical context.47 48 The selec-
tion of patients eligible for immunotherapy by PD-L1 
expression may improve the cost-effectiveness of the 
treatment and decrease the economic burden of the 
treatment.47 48
Nevertheless, about 10% of patients have some benefit 
with immunotherapy despite being PD-L1 negative.31 
Furthermore, the median OS among all PD-L1-neg-
ative patients is equal with immunotherapy and with 
chemotherapy.31
Figure 1 The guideline for the treatment of non-small cell lung cancer (NSCLC) after the development of immunotherapy.
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Further investigation is required in order to refine 
PD-L1 expression as a predictive biomarker.
further directions for the first-Line treAtment of 
pd-L1-negAtive pAtients
immunotherapy plus chemotherapy
After successful demonstration of efficacy as single-
agents, clinical trials are currently assessing PD-1 and 
PD-L1 inhibitors combined with chemotherapy, other 
ICs and targeted therapies, in attempts to further 
improve outcomes for patients with low PD-L1 expression 
advanced NSCLC.
In an open-label phase II cohort study, 123 patients 
were randomised to receive pemetrexed/carboplatin 
(63) or in combination with pembrolizumab(60).49 In 
both groups, chemotherapy was given for four cycles 
followed by indefinite pemetrexed maintenance while in 
the investigational arm, pembrolizumab was continued 
for 24 months.49
The primary end point for this study was achieved, 
with an improvement in ORR.49 The ORR was 55% with 
pembrolizumab plus chemotherapy compared with 
29% for chemotherapy alone (p=0.0016).49 The risk of 
progression was also reduced by 47% with pembrolizumab 
(median PFS 13 months vs 8.9 months; p=0.0102).49 The 
follow-up was insufficient to evaluate the OS (median 
not reached in both arms).49 In assessments of PD-L1 
staining, patients with PD-L1 <1% had an ORR of 57% 
with pembrolizumab combination compared with 13% in 
the chemotherapy arm.49
Pembrolizumab was well tolerated.49 The most 
frequent all-grade treatment-related adverse events in the 
pembrolizumab combination and chemotherapy isolated 
arms, respectively, were fatigue (64% vs 40%), nausea 
(58% vs 44%), anaemia (32% vs 53%), vomiting (25% vs 
18%) and diarrhoea (20% vs 10%).49 Adverse events led 
to treatment discontinuations for 10% of patients in the 
pembrolizumab arm compared with 13% in the control 
group.49
Early findings for chemotherapy combined with PD-1/
PD-L1 inhibitors showed promising signs of efficacy, 
resulting in the initiation of several phase III trials and 
the recent approval of this combination for use in the 
USA by Food and Drug Administration. Nevertheless, 
combination strategies have some limitations. The first is 
the need to confirm putative benefits in a phase III trial. 
The second one is the high cost of aggregating treatment 
with immunotherapy and chemotherapy.
immunotherapy combinations
In a large phase I study, a single arm assessed the combi-
nation of nivolumab with ipilimumab (an immune 
checkpoint inhibitor that stimulate lymphocyte activity 
by binding of CTLA-4 receptor).50 In a report of this 
study, 77 chemotherapy-naive patients received ipilim-
umab every 6 weeks or every 12 weeks plus nivolumab 
every 2 weeks until disease progression or unacceptable 
toxicity.50Thirty-three patients (43%) achieved a partial 
response and the median PFS was 8.1 months for the 
nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/
kg each 12 weeks arm and 3.9 months for the nivolumab 
3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 
weeks.50 The median OS was not reached in both arms.50 
The combination was effective regardless of PD-L1 
expression.50
Unfortunately, the majority of patients (82%) had some 
adverse event and one third had a severe adverse event.50 
The most common severe immune-related adverse events 
were diarrhoea (5%), colitis (5%) and pneumonitis 
(4%).50
Another phase Ib trial assessed the combination of a 
PD-L1 inhibitor (durvalumab) with a CTLA-4 inhibitor 
(tremelimumab).51 This study enrolled 102 patients with 
immunotherapy-naive (6% was also chemotherapy-naive) 
for treatment.51
The ORR was 23% in the combined tremelimumab 
1 mg/kg cohort and the benefit was independent of 
PD-L1 expression.51 Two of nine patients with PD-L1-pos-
itive tumours and 4 of 10 patients with no PD-L1 staining 
achieved objective response.51 The study did not assess 
PFS and OS.51
Once again, the safety of this combination was the major 
concern. The most frequent treatment-related grade 3 
and 4 adverse events were diarrhoea (11%), colitis (9%) 
and increased lipase (8%).51 Discontinuations attribut-
able to toxicity occurred in 29 of 102 patients.51 Three 
deaths were related to treatment.51
The combination of CTLA-4 inhibitors with PD-1/
PD-L1 inhibitors has significant limitations showing 
incorporation into the clinical practice. The main 
concern is the very high cost of these combinations. The 
clinical outcomes of these combinations must be signifi-
cantly better than standard therapy to achieve economy. 
The other limitation is the harmful toxicity profile of this 
treatment. The adverse events observed are worse than 
expected with single agent immunotherapy. This may be 
a result of a toxic synergism between these ICIs.
The combination of anti-PD1/anti-PDL1 with other 
ICIs has several limitations. Translating theoretical and 
in vitro synergy into in vivo synergy and subsequent clin-
ical benefit for patients is challenging. Another limitation 
is the very high cost of these combinations. Finally, the 
toxicity profile of these combinations seems to be more 
harmful than expected (such as observed with anti-
CTLA4 plus anti-PD1/anti-PDL1).
vaccines
In NSCLC context, vaccine therapy may be divided into 
TC vaccines (autologous or allogeneic TCs), and anti-
gen-based vaccines. In general vaccines are administered 
with adjuvants, whose purpose is to stimulate the immune 
response without have intrinsic antigen effect.52 53 
Although vaccines have been evaluated for the treatment 
of NSCLC at different stages, they almost all failed to 
demonstrate any benefit.
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 ► Vaccines as maintenance therapy:
MUC1 is overexpressed and aberrantly glycosylated in 
NSCLC, making it a target for immunotherapy.54 A phase 
IIB study randomised 171 patients with advanced NSCLC 
without disease progression after first-line chemotherapy 
to receive tecemotide (a peptide vaccine targeting 
MUC1) or best supportive care alone.54 The median OS 
was higher in the vaccine group, however, this was not 
statistically significant (17.4 months vs 13 months; HR 
0.75; 95% CI 0.53 to 1.04).54
Lucanix (belagenpumatucel-L) is a tumour vaccine, 
which is a compound of four allogeneic NSCLC cell 
lines modified with transforming growth factor-b2-an-
tisense plasmid.55 A phase II trial randomised 532 
patients with advanced NSCLC without progression after 
platinum-based chemotherapy to maintenance belagen-
pumatucel-L or placebo.55 Although the vaccine was well 
tolerated, there was not any benefit with this treatment.55 
The median PFS was 4.3 months with vaccine versus 4 
months with placebo.55 The median OS was 20.3 months 
with vaccine versus 17.8 months with placebo (HR 0.94; 
95% CI 0.73 to 1.20).55
Racotumomab-alum is a tumour vaccine targeting 
the NeuGGM3 tumour-associated ganglioside.56 It was 
assessed in a phase II study, which randomised 176 
patients with advanced NSCLC who achieved at least 
stable disease after first-line chemotherapy to receive 
racotumomab-alum or placebo.56 The vaccine improved 
not only the median PFS (5.3 months vs 3.9 months; HR 
0.73; 95% CI 0.53 to 0.99), but also the median OS (8.2 
months vs 6.8 months; HR 0.63; 95% CI 0.46 to 0.87) with 
racotumomab-alum group compared with placebo.56
Figure 2 Hypothetical options for the first-line treatment of non-small cell lung cancer for patients with programmed death 
receptor ligand-1 (PD-L1)<50%. 
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Vx-001 is an HLA-A*0201-restricted vaccine targeting 
the human telomerase reverse transcriptase tumour 
antigen.57 Patients with positive HLA-A*0201 tumour 
antigen and residual or progressive disease after first-line 
chemotherapy were treated by six doses of Vx-001 in a 
phase II trial.57 The ORR and stable disease rate were 7% 
and 28%, respectively.57 The median PFS was 3.8 months 
and the median OS was 19 months.57 In a subset anal-
ysis, patients who mounted immune responses (defined 
by number of interferon-g-spots-forming-cells from blood 
mononuclear cells significantly increasing after vacci-
nation compared with the background) had prolonged 
median OS compared with patients who did not mount a 
response (40 months vs 9.2 months; p=0.02).57 The most 
common adverse events were nausea, fatigue, anaemia 
and injection-site reaction.57
 ► Vaccines as first-line treatment
The TG4010 vaccine (modified vaccine virus Ankara 
containing the sequence for interleukin-2 and MUC-1) 
has a tumour-specific antigen sequence which is over-
expressed in various epithelial tumours, such as lung 
cancer.58 A phase IIb/III trial compared the addition of 
TG4010 immunotherapy to chemotherapy with placebo 
plus chemotherapy inpatients with advanced NSCLC and 
MUC1 expression ≥50%.58 The study randomised 222 
patients to receive TG4010 versus placebo, in addition 
to platinum doublet-based chemotherapy.58 The primary 
endpoint of improvement in PFS was achieved (median 
PFS 5.9 months vs 5.1 months; HR 0.74; 95% CI 0.55 to 
0.98).58 Otherwise, the median OS was also superior for 
TG4010 compared with placebo (12.7 months vs 10.6 
months; HR 0.78; 95% CI 0.57 to 1.06).58 Most common 
adverse events were grade 1 to 2 injection-site reactions.58
 ► Vaccines in previously treated patients
A phase II study has evaluated a tumour vaccine whose 
composition is a granulocyte-macrophage colony-stimu-
lating factor–producing and CD40L-expressing bystander 
cell line and allogeneic TCs.59 Twenty-four patients were 
enrolled with a median of four previous lines of systemic 
treatment.59 There was no objective response, the median 
PFS was 1.7 months and the median OS was 7.9 months.59 
The most common adverse events were mild headache 
and injection site reaction.59
GVAX is a tumour vaccine consisting of autologous 
TCs mixed with an allogeneic cell line secreting gran-
ulocyte-macrophage colony-stimulating factor studied 
in a phase I/II trial.60 Eighty-six patients with advanced 
NSCLC had tumour harvested to vaccine preparation and 
49 patients received the vaccine treatment.60 There was 
no objective responses, the median PFS was 4.4 months 
and the median OS was 7 months.60 Common adverse 
events included mild injection site reactions, fatigue, 
dyspnoea, nausea and fever.60
Adaptive t-cell therapy
Adaptive T-cell therapy is the reinfusion back into the 
patient of expanded populations of tumour-infiltrating 
lymphocytes (TILs) collected from tumour resection 
specimens. Some patients with melanoma had response 
with this therapy,61–63 although this strategy may be 
harder for most other solid tumour types due to diffi-
culty in identification and ex vivo culturing of TILs.
Consequently, an alternative strategy has been 
developed, involving genetically modifying otherwise 
tumour non-reactive T cells to bear tumour reactivity. 
CD8+ and CD4+ T cells are collected via leukapharesis, 
and expanded via coculture with artificial antigen-pre-
senting cells. The final result is a T cell expressing either 
a T cell receptor (TCR) clone or a chimeric antigen 
receptor (CAR), specific to a tumour-associated antigen 
(TAA).64
TAAs that have been targeted via engineered T cells 
in lung cancer include: (1) NYESO1 (NCT01697527, 
NCT01967823), a cancer testis antigen found in 
up to 30% of lung cancers65 (2) VEGF receptor 2 
(NCT01218867), expressed in the majority of lung 
cancer samples66 (3) MAGE-A3 (NCT02111850), found 
over 40% of lung cancers.67
Although enthusiastic results inpatients with synovial 
cell sarcoma, melanoma and leukaemia, Engineered 
T-cell therapy has not demonstrated efficacy in solid 
tumours.64 68 69 The only exception is CAR-engineered 
T cells that showed partial responses in a small propor-
tion of patients with mesothelioma.70
There are several aspects that inhibits adoptive T-cell 
therapy efficacy: heterogeneous TAA expression and TAA 
shedding, short T-cell survival/persistence, suboptimal 
T-cell trafficking, the barrier of tumour-associated stroma, 
the presence of suppressive immune cells, upregulation 
of inhibitory checkpoints, the expression of regulatory 
genes, lack of oxygen and cellular nutrients and immuno-
suppressive soluble factors.64
There are many problems to solve, based on tumour 
and T-cell microenvironments, to develop adoptive T-cell 
therapy into a treatment for lung cancer.
Figure 2 shows hypothetical options for the first-line 
treatment of NSCLC for patients with PD2L1< 50%.
concLusion
Immunotherapy has changed the treatment of NSCLC. 
While it has become a second-line therapy of choice, 
recent clinical trial data is shifting the paradigm in the 
first-line treatment as well, for a limited proportion of 
patients (30% with PD-L1≥50%). Further strategies are 
under development in order to trump traditional chemo-
therapy and extend the benefits to a higher proportion 
of patients.
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